Suceveanu, A.-I.; Mazilu, L.; Katsiki, N.; Parepa, I.; Voinea, F.; Pantea-Stoian, A.; Rizzo, M.; Botea, F.; Herlea, V.; Serban, D.;
et al. NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. Metabolites 2020, 10, 448.
https://doi.org/10.3390/metabo10110448
AMA Style
Suceveanu A-I, Mazilu L, Katsiki N, Parepa I, Voinea F, Pantea-Stoian A, Rizzo M, Botea F, Herlea V, Serban D,
et al. NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. Metabolites. 2020; 10(11):448.
https://doi.org/10.3390/metabo10110448
Chicago/Turabian Style
Suceveanu, Andra-Iulia, Laura Mazilu, Niki Katsiki, Irinel Parepa, Felix Voinea, Anca Pantea-Stoian, Manfredi Rizzo, Florin Botea, Vlad Herlea, Dragos Serban,
and et al. 2020. "NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome" Metabolites 10, no. 11: 448.
https://doi.org/10.3390/metabo10110448
APA Style
Suceveanu, A. -I., Mazilu, L., Katsiki, N., Parepa, I., Voinea, F., Pantea-Stoian, A., Rizzo, M., Botea, F., Herlea, V., Serban, D., & Suceveanu, A. -P.
(2020). NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome. Metabolites, 10(11), 448.
https://doi.org/10.3390/metabo10110448
